The original success of Sildenafil undeniably reshaped the pharmaceutical landscape, but placing funds in companies primarily reliant on off-patent versions presents a uncertain picture. While early returns were significant, the expiration of patents and the emergence of discounted alternatives have weakened sales. Therefore, a thorough analysis of